TG Therapeutics presents seven‑year BRIUMVI efficacy data and new dosing updates
TG Therapeutics disclosed long‑term results for its multiple‑sclerosis therapy BRIUMVI at the 10th Joint ACTRIMS‑ECTRIMS Meeting. Seven‑year follow‑up of the ULTIMATE I and II trials showed that about 88% of continuously treated patients remained free from confirmed disability progression. The company also reported Phase 1 subcutaneous data that could enable quarterly dosing and Phase 3 findings that may simplify infusion schedules.
Why it matters
The durability of BRIUMVI’s effect could strengthen the drug’s market position and support future sales growth, according to the company’s presentation. The stock trades at a trailing P/E of 19.86×, well below its five‑year median of 40.24×, suggesting a valuation discount that may interest investors.
Key facts
- 1Approximately 88% of patients treated with BRIUMVI remained free from confirmed disability progression over seven years. gurufocus.com
- 2Market capitalization was $8.35 billion. gurufocus.com
- 3Trailing twelve‑month P/E ratio was 19.86×. gurufocus.com
- 4GF Score™ was 61 out of 100. gurufocus.com
- 5Insiders sold roughly $0.4 million of shares over the past 12 months with no purchases. gurufocus.com
- 6Six premium gurus hold TGTX shares; five increased their stakes and one reduced exposure recently. gurufocus.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.